LogicBio Therapeutics (OTCMKTS:LOGC) Hits New 1-Year High – Here’s What Happened

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $15.25 and last traded at $15.1850, with a volume of 29037 shares traded. The stock had previously closed at $14.87.

LogicBio Therapeutics Stock Performance

The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The stock’s 50 day moving average is $11.35 and its 200 day moving average is $9.60. The stock has a market capitalization of $685.05 million, a price-to-earnings ratio of -20.52 and a beta of 2.11.

LogicBio Therapeutics (OTCMKTS:LOGC) last announced its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10). The business had revenue of $33.60 million for the quarter, compared to the consensus estimate of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.